18F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors
- 437 Downloads
Tumor necrosis is one of the indicators of tumor aggressiveness. 18F-fluoromisonidazole (FMISO) is the most widely used positron emission tomography (PET) tracer to evaluate severe hypoxia in vivo. Because severe hypoxia causes necrosis, we hypothesized that intratumoral necrosis can be detected by FMISO PET in brain tumors regardless of their histopathology. We applied FMISO PET to various types of brain tumors before tumor resection and evaluated the correlation between histopathological necrosis and FMISO uptake.
This study included 59 brain tumor patients who underwent FMISO PET/computed tomography before any treatments. According to the pathological diagnosis, the brain tumors were divided into three groups: astrocytomas (group 1), neuroepithelial tumors except for astrocytomas (group 2), and others (group 3). Two experienced neuropathologists evaluated the presence of necrosis in consensus. FMISO uptake in the tumor was evaluated visually and semi-quantitatively using the tumor-to-normal cerebellum ratio (TNR).
In visual analyses, 26/27 cases in the FMISO-positive group presented with necrosis, whereas 28/32 cases in the FMISO-negative group did not show necrosis. Mean TNRs with and without necrosis were 3.49 ± 0.97 and 1.43 ± 0.42 (p < 0.00001) in group 1, 2.91 ± 0.83 and 1.44 ± 0.20 (p < 0.005) in group 2, and 2.63 ± 1.16 and 1.35 ± 0.23 (p < 0.05) in group 3, respectively. Using a cut-off value of TNR = 1.67, which was calculated by normal reference regions of interest, we could predict necrosis with sensitivity, specificity, and accuracy of 96.7, 93.1, and 94.9 %, respectively.
FMISO uptake within the lesion indicated the presence of histological micro-necrosis. When we used a TNR of 1.67 as the cut-off value, intratumoral micro-necrosis was sufficiently predictable. Because the presence of necrosis implies a poor prognosis, our results suggest that FMISO PET could provide important information for treatment decisions or surgical strategies of any type of brain tumor.
KeywordsNecrosis FMISO PET Hypoxia Brain tumor Biopsy Histology
The authors thank the staff at the Departments of Nuclear Medicine, Molecular Imaging, Radiology, Neurosurgery, and Cancer Pathology of Hokkaido University Graduate School of Medicine, and Department of Surgical Pathology of Hokkaido University Hospital.
Compliance with Ethical Standards
The authors declare that they have no conflict of interest. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
- 3.Miller CR, Dunham CP, Scheithauer BW, Perry A. Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol: Off J Am Soc Clin Oncol. 2006;24(34):5419–26. doi: 10.1200/JCO.2006.08.1497.CrossRefGoogle Scholar
- 13.Hirata K, Terasaka S, Shiga T, Hattori N, Magota K, Kobayashi H, et al. (1)(8)F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas. Eur J Nucl Med Mol Imaging. 2012;39(5):760–70. doi: 10.1007/s00259-011-2037-0.CrossRefPubMedGoogle Scholar
- 14.Grunbaum Z, Freauff SJ, Krohn KA, Wilbur DS, Magee S, Rasey JS. Synthesis and characterization of congeners of misonidazole for imaging hypoxia. J Nucl Med: Off Publ Soc Nucl Med. 1987;28(1):68–75.Google Scholar
- 22.Yamaguchi S, Terasaka S, Kobayashi H, Asaoka K, Motegi H, Nishihara H, et al. Prognostic factors for survival in patients with high-grade meningioma and recurrence-risk stratification for application of radiotherapy. PLoS One. 2014;9(5), e97108. doi: 10.1371/journal.pone.0097108.CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Szeto MD, Chakraborty G, Hadley J, Rockne R, Muzi M, Alvord Jr EC, et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res. 2009;69(10):4502–9. doi: 10.1158/0008-5472.CAN-08-3884.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Spence AM, Muzi M, Swanson KR, O’Sullivan F, Rockhill JK, Rajendran JG, et al. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res: Off J Am Assoc Cancer Res. 2008;14(9):2623–30. doi: 10.1158/1078-0432.CCR-07-4995.CrossRefGoogle Scholar
- 26.Kawai N, Lin W, Cao WD, Ogawa D, Miyake K, Haba R, et al. Correlation between 18F-fluoromisonidazole PET and expression of HIF-1alpha and VEGF in newly diagnosed and recurrent malignant gliomas. Eur J Nucl Med Mol Imaging. 2014;41(10):1870–8. doi: 10.1007/s00259-014-2776-9.CrossRefPubMedGoogle Scholar